

22. An isolated nonapeptide consisting of the amino acid sequence EVDPIGHLY.
23. An isolated nucleic acid molecule consisting of a nucleotide sequence encoding the nonapeptide EVDPIGHLY.
24. An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A1 molecule and a nonapeptide having the amino acid sequence EVDPIGHLY.
25. An isolated cytolytic T cell line which specifically recognizes a complex of an HLA-A1 molecule and a nonapeptide consisting of the amino acid sequence EVDPIGHLY.
26. An isolated antigenic HLA-A1 binding peptide derived from a MAGE protein having the following formula:

Xaa<sub>1</sub>Xaa<sub>2</sub>Xaa<sub>3</sub>Xaa<sub>4</sub>Xaa<sub>5</sub>Xaa<sub>6</sub>Xaa<sub>7</sub>Xaa<sub>8</sub>Xaa<sub>9</sub>

wherein Xaa<sub>3</sub> is Asp or Glu, and Xaa<sub>9</sub> is Tyr, and

said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said nonapeptide, with the proviso that said nonapeptide is not EADPTGHSY.--

## REMARKS

Support for new claims 21-26 is provided throughout the specification, drawings and original claims 1-20, which are identical to that filed in parent application 08/103,396. The Examiner's attention is directed in particular to support provided at least by the following: page 112, first sequence of Table 23(h).

Applicants wish to point out that the present application is related to U.S. patent application 08/186,266, filed January 25, 1994, now U.S. Patent 5,662,907, which is involved in pending Patent Interference No. 104,541 before the USPTO Board of Patent Appeals and Interferences.